Evidence map›Paper›PMID 25985157›Full record

ArticleSensors (Basel, Switzerland)2015

MMP-2/9-Specific Activatable Lifetime Imaging Agent.

Marcus T M Rood, Marcel Raspe, Jan Bart ten Hove, Kees Jalink, Aldrik H Velders, Fijs W B van Leeuwen

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Imaging the Tumor Microenvironment.Advances in experimental medicine and biology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marcus T M RoodInterventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden 2300RC, The Netherlands. m.t.m.rood@lumc.nl.
Marcel RaspeDivision of Cell Biology I, Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands. m.raspe@nki.nl.
Jan Bart ten HoveInterventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden 2300RC, The Netherlands. janbart.tenhove@wur.nl.
Kees JalinkDivision of Cell Biology I, Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands. k.jalink@nki.nl.
Aldrik H VeldersInterventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden 2300RC, The Netherlands. aldrik.velders@wur.nl.
Fijs W B van LeeuwenInterventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden 2300RC, The Netherlands. f.w.b.van_leeuwen@lumc.nl.

Funding

European Research Council 306890
6 · The paper itself

Abstract

Optical (molecular) imaging can benefit from a combination of the high signal-to-background ratio of activatable fluorescence imaging with the high specificity of luminescence lifetime imaging. To allow for this combination, both imaging techniques were integrated in a single imaging agent, a so-called activatable lifetime imaging agent. Important in the design of this imaging agent is the use of two luminophores that are tethered by a specific peptide with a hairpin-motive that ensured close proximity of the two while also having a specific amino acid sequence available for enzymatic cleavage by tumor-related MMP-2/9. Ir(ppy)3 and Cy5 were used because in close proximity the emission intensities of both luminophores were quenched and the influence of Cy5 shortens the Ir(ppy)3 luminescence lifetime from 98 ns to 30 ns. Upon cleavage in vitro, both effects are undone, yielding an increase in Ir(ppy)3 and Cy5 luminescence and a restoration of Ir(ppy)3 luminescence lifetime to 94 ns. As a reference for the luminescence activation, a similar imaging agent with the more common Cy3-Cy5 fluorophore pair was used. Our findings underline that the combination of enzymatic signal activation with lifetime imaging is possible and that it provides a promising method in the design of future disease specific imaging agents.

Indexed as

CarbocyaninesCell Line, TumorCytological TechniquesFluorescence Resonance Energy TransferFluorescent DyesHumansIridiumMatrix Metalloproteinase 2Matrix Metalloproteinase 9Molecular ImagingCarbocyaninescyanine dye 5Fluorescent DyesIridiumMatrix Metalloproteinase 2Matrix Metalloproteinase 9enzymatic activationfluorescenceFRETiridiumlifetime imagingluminescenceMMP

Identifiers

PMID25985157
PMCPMC4481940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.